Table 8.

Multinomial Logit Regression Model on Choosing Between Daily Pill Version of Antiretroviral Therapy Versus Long-Acting Injectable (LAI) Versus a New HIV Remission Strategy (United States, 2018)

	Selecting LAI over daily pill version of ART			Selecting remission strategy over daily pill version of ART
	Relative risk ratio	p	95% CI	Relative risk ratio	p	95% CI
Relatively more risk averse than other participants	0.96	.086	0.92–1.01	0.93a	.005	0.89–0.98
Relatively more motivated by benefits than other participants	1.07a	.004	1.02–1.12	1.08a	.002	1.03–1.14
Cis or trans woman (vs. cis man)	1.02	.981	0.13–7.86	0.72	.778	0.08–6.92
Age	0.97	.551	0.89–1.06	0.96	.380	0.86–1.06
African American/black (vs. Caucasian/white)	3.48	.435	0.15–79	2.51	.592	0.09–72
Other race (vs. Caucasian/white)	1.66	.717	0.11–26	0	.989
Hispanic	0.37	.495	0.02–6.30	0.72	.828	0.04–14.09
Some college or 2-year degree (vs. high school diploma)	2.73	.458	0.19–39	10.45	.162	0.39–281
4-year college degree (vs. high school diploma)	6.74	.221	0.32–143	21.05	.103	0.54–822
Master's or Doctorate degree (vs. high school diploma)	17.58	.174	0.28–1,096	156.11b	.031	1.58–15,464
Married or living with a partner	2.37	.463	0.24–24	4.12	.261	0.35–49
Annual household income exceeds $50,000	0.61	.746	0.03–12	1.85	.712	0.07–48
Midwest (vs. Northeast)	>1,000	.989		>1,000	.990
South (vs. Northeast)	9.57	.091	0.70–131	3.23	.414	0.19–54
West (vs. Northeast)	2.12	.535	0.20–23	0.85	.906	0.06–12
Has a regular, full-time job (vs. no job)	4.71	.244	0.35–64	5.59	.242	0.31–100
Has a regular, part-time job (vs. no job)	3.16	.422	0.19–52	0.18	.360	0–7.05
Mostly able to pay expenses but late (vs. unable to pay expenses)	0.21	.386	0.01–7.14	0.03	.079	0–1.47
Able to pay expenses, no savings (vs. unable to pay expenses)	0.40	.608	0.01–13	0.12	.259	0–4.72
Able to pay expenses, has savings (vs. unable to pay expenses)	0.41	.670	0.01–26	0.02	.082	0–1.64
Percentage of lifetime living with HIV or AIDS diagnosis	0.57	.825	0–80	1.14	.962	0–278
Self-assessed health status is in the poorest quartile of participants	3.38	.340	0.28–41	6.95	.165	0.45–107
Volunteered for an HIV treatment trial in the past	0.58	.676	0.05–7.37	1.47	.776	0.1–21
Only 0 or 1 pill or tablet of HIV medication per day (vs. more)	1.89	.533	0.25–14	1.87	.583	0.2–17
Take HIV medication two or more times per day (vs. once/never)	6.05	.380	0.11–338	2.25	.708	0.03–157
HIV medication timing is affected by food/other drugs	5.01	.142	0.58–43	7.54	.085	0.76–75
Current HIV medication causes side effects	2.59	.363	0.33–20	1.52	.708	0.17–14

n = 153. p = 0.0037. Pseudo R² = 0.3296.

The listed coefficients indicate the relative risk ratio of each variable associated with selecting long-acting ART injectables over daily ART (left columns) and the relative risk ratio of each variable associated with selecting a new HIV remission strategy over daily pill version of ART (right columns).

^aStatistically significant at 1% level.

^bStatistically significant at 5% level.

CI, confidence interval; LAI, long-acting injectable.